STOCK TITAN

Tilray Brands (TLRY) Stock Price, News & Analysis

TLRY NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
42 252 sessions, November 6, 2025 to November 6, 2026
Largest daily move
+44.1% close of December 12, 2025
1-year change
-75.9% closing prices, November 6, 2025 to November 6, 2026
1-month change
-22.8% closing prices, October 6, 2026 to November 6, 2026

Company Description

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) is a global lifestyle and consumer packaged goods company operating at the intersection of the cannabis, beverage, wellness, and entertainment industries. According to the company’s public disclosures, Tilray’s platform supports more than 40 brands across over 20 countries, with operations in Canada, the United States, Europe, Australia, and Latin America. The company’s activities span cannabis, hemp-based foods, craft beverages, and related consumer products that are positioned around social connection, wellness, and premium lifestyle experiences.

Tilray describes its mission as becoming a premium lifestyle company with a house of brands and products that inspire joy, wellness, and memorable experiences. Within cannabis, the company highlights comprehensive offerings that include adult-use and medical products across multiple markets. Through its wellness and hemp-based food lines, Tilray participates in plant-based and cannabinoid-focused categories, while its beverage business includes craft beers, premium spirits, ready-to-drink cocktails, non-alcoholic beers, and hemp-derived THC beverages, as reflected in recent product announcements and seasonal collections.

Business Segments and Brand Platform

Tilray’s public communications reference a diversified portfolio spanning cannabis, beverage, wellness, and distribution sectors. In its financial reporting, the company identifies cannabis, beverage, wellness, and distribution (including Tilray Pharma) as key revenue contributors. Cannabis activities include international medical cannabis exports, Canadian adult-use cannabis, and branded products sold under subsidiaries such as Aphria Inc. The distribution segment includes Tilray Pharma, which the company describes as a medical distribution platform.

In beverages, Tilray highlights a broad lineup of craft beer and spirits brands as well as ready-to-drink cocktails and hemp-derived THC beverages. Its holiday and Dry January guides showcase brands such as Breckenridge (whiskeys and spirits), 10 Barrel Brewing, Blue Point Brewing, Montauk Brewing, SweetWater Brewing, Terrapin Beer Co., Atwater Brewery, Widmer Brothers, and various hemp-derived THC beverage brands like Happy Flower and Fizzy Jane’s. The company also promotes non-alcoholic offerings, including non-alcoholic beers and zero-proof spirits under the Mock One brand, as part of a mindful drinking and “sober curious” positioning.

Within cannabis, Tilray’s brand portfolio includes Good Supply, Redecan, Broken Coast, Mollo, XMG, and Chowie, among others, as highlighted in its Canadian product announcements and gift guides. These brands cover categories such as pre-rolls, flower, vapes, live resin products, cannabis-infused beverages, and edibles. Tilray notes that many cannabis products in Canada are sold through its wholly owned subsidiary Aphria Inc., a licensed producer under the Cannabis Act.

Medical Cannabis and Tilray Medical

Tilray Medical is a division of Tilray Brands focused on medical cannabis healthcare. The company states that it operates in federally regulated medical cannabis markets globally and has worked with regulators, physicians, hospitals, and research institutions. Tilray reports that it offers more than 200 registered medical cannabis products across international markets for therapeutic use and has served over 500,000 registered patients globally. It also notes participation in more than 15 medical cannabis studies and clinical trials in partnership with hospitals and physicians, addressing conditions such as pediatric epilepsy, cancer-induced nausea, PTSD, pain, anxiety, essential tremors, alcohol use disorder, fibromyalgia, glioblastoma, and cannabinoids and driving performance.

Following U.S. federal cannabis rescheduling, Tilray announced the formation of Tilray Medical USA, Inc. as part of a strategic framework to advance its U.S. medical cannabis operations. The company emphasizes its existing compliance systems, scientific expertise, and governance practices developed in other regulated markets, and indicates that it plans to introduce medical-grade cannabis products in targeted therapeutic formats as regulations allow.

Geographic Footprint and Operations

Tilray states that it has operations in Canada, the United States, Europe, Australia, and Latin America. Its disclosures describe an established global footprint that supports its cannabis, beverage, wellness, and distribution activities. In Canada, the company is active in adult-use cannabis, medical cannabis, and cannabis-infused beverages, with brands such as Good Supply, Redecan, Mollo, XMG, and others available through provincial retailers and licensed online channels. In the United States, Tilray’s exposure includes beverage alcohol brands, non-alcoholic beverages, hemp-derived THC drinks, and, through Tilray Medical USA, a framework for medical cannabis expansion in line with federal rescheduling developments.

Internationally, Tilray highlights its role in medical cannabis export markets and notes that Tilray Pharma operates as a distribution platform. The company’s communications emphasize its experience in tightly regulated medical cannabis environments and its focus on quality, compliance, and patient safety in those markets.

Financial Reporting and Corporate Actions

Tilray files reports with the U.S. Securities and Exchange Commission and is listed on The Nasdaq Global Select Market under the symbol TLRY, with its common stock also trading on the Toronto Stock Exchange under the same symbol. In an 8-K filing and related press release, the company disclosed that its board of directors approved a one-for-ten reverse stock split of its common stock, effective as of December 1, 2025, with trading on a split-adjusted basis beginning December 2, 2025, under the existing symbol TLRY and a new CUSIP number. The company stated that the reverse split was intended to align its number of shares outstanding with companies of similar size and scope, make the stock more attractive to certain institutional shareholders, and reduce expenditures associated with its annual meeting of stockholders.

In its financial communications, Tilray presents results across cannabis, beverage, wellness, and distribution segments and uses both GAAP and non-GAAP measures such as adjusted gross profit, adjusted gross margin, adjusted EBITDA, adjusted net income (loss), free cash flow, and net (debt) cash. The company explains that these non-GAAP measures are intended to provide additional insight into operational trends and period-over-period comparisons, while cautioning that they should not be viewed as substitutes for GAAP metrics.

Product and Category Highlights

Tilray’s news releases provide detailed examples of its product categories. In beverages, the company showcases:

  • Premium spirits under the Breckenridge brand, including whiskeys and specialty finishes.
  • Ready-to-drink cocktails from brands such as 10 Barrel Brewing and Cruisies.
  • Craft beers from regional breweries including Blue Point Brewing, Montauk Brewing, SweetWater Brewing, Terrapin Beer Co., Atwater Brewery, Breckenridge Brewery, Hop Valley Brewing, and Widmer Brothers.
  • Non-alcoholic offerings such as Runner’s High non-alcoholic beer, Montauk N.A. Golden, and Mock One zero-proof spirits.
  • Hemp-derived THC beverages under brands like Happy Flower and Fizzy Jane’s.

In cannabis and wellness, Tilray’s communications highlight:

  • Good Supply pre-rolls, flower, vapes, and concentrates, including 510-thread cartridges in strains such as Pineapple Express and Blue Dream.
  • Redecan products, including Redees pre-rolls and Amped Live Resin Liquid Diamond vape cartridges that combine live resin and liquid diamonds.
  • Broken Coast craft cannabis flower.
  • Mollo cannabis-infused seltzers and beverages, including various THC and CBG combinations.
  • XMG beverages and edibles, including Atomic Sours and XMG Zero sugar-free drinks.
  • Chowie cannabis-infused chocolates.

Corporate Governance and Shareholder Matters

Tilray’s definitive proxy statement describes a classified board of directors divided into three classes, with directors standing for election on a staggered basis. At its 2025 annual meeting of stockholders, the company presented proposals including the election of a Class I director, ratification of its independent registered public accounting firm, an advisory vote on executive compensation, and governance changes to declassify the board and modify director removal provisions. Voting results disclosed in an 8-K show that the director election and auditor ratification were approved, the advisory compensation resolution received majority support, and the governance proposal did not receive sufficient votes to pass.

The proxy materials also describe the company’s use of a virtual annual meeting format via live webcast, allowing stockholders to vote and submit questions online. Tilray notes that its common stock is its only class of voting securities and that a specified portion of outstanding shares is required to constitute a quorum at the annual meeting.

Position in the Cannabis and Consumer Packaged Goods Landscape

Across its public statements, Tilray characterizes itself as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, with an emphasis on elevating lives through “moments of connection.” Its brand and product strategy centers on lifestyle positioning, mindful consumption trends, and the integration of cannabis and hemp-derived ingredients into beverages and other consumer categories. The company’s disclosures emphasize its multi-category platform, international footprint, and focus on regulated medical cannabis markets as key elements of its business model.

Stock Performance

$2.92
+0.00%
+0.00
After hoursChange vs the $2.92 closeLast updated: November 6, 2026 at 19:41
-75.9%
Performance 1 year
$431.5M

Tilray Brands (TLRY) closed at $2.92 on November 6, 2026. Over the past 12 months, the price has lost 75.9%.

See what a $1,000 investment in TLRY would be worth today

Average down calculator for TLRY

TLRY Metrics & Rankings

Price returns through November 6, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Tilray Brands has 10 recent news articles, with the latest published 7 days ago. Of the recent coverage, 3 articles coincided with positive price movement and 7 with negative movement. View all TLRY news →

Financial Highlights

Tilray Brands generated $915.5M in revenue in FY2026, retaining a 28.4% gross margin, operating income reached -$63.0M (-6.9% operating margin), and net income was -$121.4M, reflecting a -13.3% net profit margin. Diluted earnings per share stood at -$1.09. The company generated -$69.1M in operating cash flow. The current ratio was 2.21, measuring current assets divided by current liabilities.

$915.5M
Revenue (FY2026)
-$121.4M
Net Income (FY2026)
-$69.1M
Operating Cash Flow

Upcoming Events

DEC
31
December 31, 2026 Marketing

Sweepstakes promotion end

SweetWater concert sweepstakes ends Dec 31, 2026; two winners per periods may choose 2026–2027 GA shows; travel gift card prizes.
DEC
31
December 31, 2026 Marketing

Voucher expiry

£10 voucher for UK pre-orders must be used online by 31 Dec 2026 with a £30 minimum spend; affects promotional redemption timing.
JAN
01
January 1, 2027 Corporate

Licensing agreement effective date

Exclusive multi-year U.S. license begins for Carlsberg, 1664, and Kronenbourg brands
YEAR
2027
2027 Regulatory

Masson EU-GMP certification

Tilray expects the Masson facility to reestablish EU-GMP certification during calendar 2027 to support medical markets and exports.
JAN
01
January 1, 2027 Corporate

Carlsberg U.S. partnership launch

Launch of exclusive U.S. brewing and commercial partnership with Carlsberg effective 2027-01-01; targets ~1M cases first year.
JAN
31
January 31, 2027 Operations

Foss operations closure

Foss operations to conclude by Jan 31, 2027; cultivation moves to Masson and pre-roll production shifts to Cayuga in phases.
DEC
2027
December 2027 Marketing

Auntie Anne Promo End

Redemption deadline for BOGO Auntie Anne's pretzel offer included with Shock Top 6-packs; redeemable in-store or via app.
Q4
2028
Q4 2028 Financial

Cost savings target deadline

Target to realize approximately $20 million annualized U.S. beverage cost savings by the end of fiscal 2028; includes facility sales.
DEC
31
December 31, 2031 Corporate

Licensing term ends

End of initial five-year term; automatic five-year renewal contingent on performance

Tilray Brands has 9 upcoming scheduled events. The next event, "Sweepstakes promotion end", is scheduled for December 31, 2026 (in 52 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the TLRY stock price.

Short Interest History

Last 12 Months

Short interest in Tilray Brands (TLRY) currently stands at 21.5 million shares, up 14.5% from the previous reporting period, representing 14.8% of the float. Since the latest stock split, short interest has increased by 30.3%, measured from December 2025.

Days to Cover History

Last 12 Months

Days to cover for Tilray Brands (TLRY) currently stands at 4.5 days, down 13.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 88.3%. Across the settlements charted above, it has ranged from 1.0 to 7.6 days.

TLRY Company Profile & Sector Positioning

Tilray Brands (TLRY) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing TLRY often look at related companies in the same sector, including Evolus, Inc. (EOLS), Kamada Ltd (KMDA), Aquestive Therapeutics, Inc. (AQST), Alpha Teknova, Inc. (TKNO), and Aurora Cannabis Inc. (ACB). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TLRY's relative position within its industry.

Frequently Asked Questions

The current stock price of Tilray Brands (TLRY) is $2.92 in after-hours trading as of November 6, 2026.

The market cap of Tilray Brands (TLRY) is approximately $431.5M. Learn more about what market capitalization means .

The FY2026 revenue of Tilray Brands (TLRY) is $915.5M, from its most recent completed fiscal year.

The FY2026 net income of Tilray Brands (TLRY) is -$121.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Tilray Brands (TLRY) is -$1.09 for FY2026, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Tilray Brands (TLRY) is -$69.1M for FY2026, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Tilray Brands (TLRY) is -13.3% for FY2026, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Tilray Brands (TLRY) is -6.9% for FY2026, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Tilray Brands (TLRY) is 28.4% for FY2026, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Tilray Brands (TLRY), current assets divided by current liabilities, was 2.21 at the end of FY2026, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Tilray Brands (TLRY) is $260.4M for FY2026, its most recent completed fiscal year.

The operating income of Tilray Brands (TLRY) is -$63.0M for FY2026, its most recent completed fiscal year. Learn about operating income.

Tilray Brands, Inc. describes itself as a global lifestyle and consumer packaged goods company operating at the nexus of cannabis, beverage, wellness, and entertainment. The company supports more than 40 brands in over 20 countries, with activities that include comprehensive cannabis offerings, hemp-based foods, craft beverages, and related consumer products.

According to its public disclosures, Tilray has operations in Canada, the United States, Europe, Australia, and Latin America. Its brand platform spans more than 40 brands distributed across over 20 countries.

Tilray is active in both adult-use and medical cannabis. It highlights comprehensive cannabis offerings, international medical cannabis markets, and Canadian adult-use products sold under brands such as Good Supply, Redecan, Broken Coast, Mollo, XMG, and others, often through its subsidiary Aphria Inc., a licensed producer under the Cannabis Act.

Tilray Medical is a division of Tilray Brands focused on medical cannabis healthcare. The company reports that it offers more than 200 registered medical cannabis products across international markets, has served over 500,000 registered patients globally, and has participated in more than 15 medical cannabis studies and clinical trials with hospitals and physicians.

Following U.S. federal cannabis rescheduling, Tilray announced the formation of Tilray Medical USA, Inc. as part of a strategic framework to expand its U.S. medical cannabis operations. The company states that this entity is intended to help it adapt to regulatory developments and introduce medical-grade cannabis products in targeted therapeutic formats as regulations allow.

Tilray’s disclosures describe a beverage portfolio that includes craft beers, premium spirits, ready-to-drink cocktails, non-alcoholic beers, and hemp-derived THC beverages. The company’s brands include breweries and distilleries such as Breckenridge, 10 Barrel Brewing, Blue Point Brewing, Montauk Brewing, SweetWater Brewing, Terrapin Beer Co., Atwater Brewery, Breckenridge Brewery, Hop Valley Brewing, and Widmer Brothers, along with hemp-derived THC beverage brands like Happy Flower and Fizzy Jane’s.

Yes. Tilray highlights non-alcoholic beers such as Runner’s High and Montauk N.A. Golden, zero-proof spirits under the Mock One brand, and hemp-derived THC beverages as part of its focus on mindful drinking and the “sober curious” movement. These products are positioned as flavor-forward alternatives that support moderation and social connection.

Tilray’s common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Global Select Market under the symbol TLRY. The company also states that its shares trade on the Toronto Stock Exchange under the same symbol.

In an 8-K filing, Tilray reported that its board approved a one-for-ten reverse stock split of its common stock, effective December 1, 2025, with trading on a split-adjusted basis beginning December 2, 2025. The company stated that the reverse split was intended to align its number of shares outstanding with companies of similar size and scope, make the stock more attractive to institutional shareholders, and reduce expenditures associated with its annual meeting of stockholders.

Tilray states that its mission is to be a leading premium lifestyle company with a house of brands and products that inspire joy, wellness, and memorable experiences. Its brand strategy emphasizes moments of connection, lifestyle positioning, and the integration of cannabis, hemp-derived ingredients, and beverages across multiple consumer categories.